RT Journal Article
SR Electronic
T1 Pharmacokinetics of Orally Administered GS-441524 in Dogs
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.02.04.429674
DO 10.1101/2021.02.04.429674
A1 Victoria C. Yan
A1 Sunada Khadka
A1 Kenisha Arthur
A1 Jeffrey J. Ackroyd
A1 Dimitra K. Georgiou
A1 Florian L. Muller
YR 2021
UL http://biorxiv.org/content/early/2021/02/05/2021.02.04.429674.abstract
AB Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury®) remains contentious. We previously described the pharmacokinetic, pharmacodynamic and toxicological rationales on the greater suitability of its parent nucleoside, GS-441524, for COVID-19 treatment. Here, we assess the oral bioavailability of GS-441524 in beagle dogs and show that plasma concentrations approximately 24-fold higher than the EC50 against SARS-CoV-2 are easily and safely sustained. These data support translation of GS-441524 as an oral agent for COVID-19.Competing Interest StatementThe authors have declared no competing interest.